NCT00794482View on ClinicalTrials.gov

Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.

PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hepatic Cirrhosis
Interventions
DRUG

NRL972

Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.

Trial Locations (1)

D-45147

University Hospital, Essen

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY

NCT00794482 - Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity. | Biotech Hunter | Biotech Hunter